Truist analyst Srikripa Devarakonda raised the firm’s price target on Protagonist Therapeutics (PTGX) to $121 from $110 and keeps a Buy rating on the shares. Following J&J’s (JNJ) commentary on Icotyde during its Q1 all, the firm reiterated its Buy rating on Protagonist as it continues to be bullish on broader Icotyde commercial opportunity. The firm added that it remains watchful of additional color on payer access, patient makeup, and additional readouts.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTGX:
- Protagonist Therapeutics price target raised to $116 from $104 at Clear Street
- Protagonist price target raised to $110 from $107 at Leerink
- Protagonist Therapeutics price target raised to $120 from $112 at Citizens
- Protagonist Therapeutics price target raised to $112 from $100 at Wedbush
- Protagonist Therapeutics price target raised to $106 from $95 at JPMorgan